

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number
WO 03/102237 A1

(51) International Patent Classification⁷: **C12Q 1/68**,
G01N 33/68, 33/74

(21) International Application Number: PCT/GB03/02369

(22) International Filing Date: 30 May 2003 (30.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0212648.0 31 May 2002 (31.05.2002) GB

(71) Applicant (for all designated States except US): **IMMUN-
OCLIN LABORATORIES LTD** [GB/GB]; Rowlandson
House, 289-293 Ballards Lane, London N12 8NP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CLERICI, Mario**
[IT/IT]; Milano University Medical School, DISP LITA
Vialba, Via GB Grassi, 74, I-20157 Milano (IT). **AN-
NONI, Giorgio** [IT/IT]; Department of Internal Medicine,
Ospedale Maggiore IRCCS, Via Pace 9, I-20122-Milan
(IT).

(74) Agent: **MCQUEEN, Andrew, Peter**; Stevens Hewlett &
Perkins, 1 St. Augustine's Place, Bristol BS1 4UD (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT WITH CYTOKINES

(57) Abstract: An inflammatory process is suggested to be involved in the pathogenesis of Alzheimer's disease (AD), a neurode-
generative disorder characterized by the presence of neuritic plaques within the cerebral cortex that are mainly composed of a small
insoluble protein of 40-42 aminoacids (amyloid protein). The biological correlates of this process are nevertheless not clear. In-
terleukin-10 (IL-10) is a cytokine that suppresses T lymphocytes and cell-mediated immunity in humans and mice and has potent
anti-inflammatory properties. To verify if IL-10 production would be impaired in AD patients we stimulated PBMC of 47 patients
and 25 age-matched healthy controls (HC) with a mitogen, a recall antigen or with amyloid peptides. IL-2 production was measured
as well in the same cultural conditions. Results showed that amyloid-specific IL-10 generation is selectively and significantly re-
duced in AD patients ($p = 0.023$). Analyses on the alleles of the IL-10 gene revealed that the genotype associated with high IL-10
production is extremely infrequent in AD individuals (2% vs. 28%). The presence of low/intermediate IL-10-producing genotypes
(GCC/ATA; ATA/ATA) was associated with an earlier age at disease onset and (ACC/ACC; ACC/ATA) with an accelerated rate of
disease progression. These data shed light on the biology of the inflammatory process involved in the pathogenesis of AD by show-
ing that the presence of low-IL-10-allelic isoforms results in an amyloid-specific impairment of IL-10 production and is associated
with the clinical severity of AD. These results lend support to the use of anti-inflammatory compounds in the therapy of this disease.

WO 03/102237 A1

THIS PAGE BLANK (USPTO)

DT09 Rec'd PCT/PTO 29 NOV 2004

TREATMENT WITH CYTOKINES FOR ALZHEIMER'S DISEASE

This invention relates to the use of cytokines in the diagnosis, treatment or prophylaxis of diseases. More particularly, the present invention relates to the use of cytokines to diagnose or treat non-neoplastic or non-leukaemic diseases such as autoimmune diseases or neurodegenerative disorders.

In the description which follows, the present invention will be described with particular reference to the most preferred embodiment of the invention which relates to the use of the cytokine interleukin-10 in the diagnosis, treatment or prophylaxis of the neurodegenerative disorder Alzheimer's disease. It is not intended to restrict the scope of the present invention to this one embodiment since the present invention finds equal utility in other disorders such as autoimmune diseases, for example multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, diabetes mellitus and asthma, other neurodegenerative disorders for example Parkinson's disease, motor neurone disease and Alzheimer's disease; chronic inflammatory diseases such as rheumatoid arthritis; and other diseases where the modulation of T-Cell function is desirable such as HIV-infection and AIDS.

Similarly, the invention has utility with all cytokines, not solely interleukin-10 and hence it is intended to include cytokines such as interleukin-1 (α or β), interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, interferon- α , interferon- β , interferon- γ , TNF- α , TNF- β , G-CSF, GM-CSF, M-CSF, and TGF- β , in the scope of the present invention.

The major cause of cognitive decline in the elderly is Alzheimer's disease (AD). Because of longer life spans worldwide, the number of people that will be affected by AD is expected to triple over the next 50 years (1). AD is a clinical syndrome characterised by complex and heterogeneous pathogenic mechanisms. The recognised genetic factors include mutations of the gene encoding the amyloid precursor protein (2), presenilin 1 and 2 (3, 4), which account for a small part of familial and usually early-onset AD cases. Genetic

factors have also been associated with the sporadic or non-familial form of the disease and the allele e4 of the apolipoprotein E (Apo E) significantly increases the risk of AD, but is neither necessary nor sufficient for the development of the disease (5- 7). Therefore other genetic and environmental factors are likely to be implicated and are actively investigated.

Molecules that take part in the inflammatory cascade are of great interest, because inflammation has repeatedly been suggested to be associated with the neurodegenerative process characteristic of the AD brain (8). Thus, reactive astrogliosis is observed both in the cortex and in the hippocampus of these patients and the glial cells are also activated within or near the neuritic plaques. Over-expression of cytokines and other inflammatory molecules are common features of the AD brain pathology (9). Additionally, epidemiological studies showed that the long term use of non-steroid anti-inflammatory drugs is associated with a decreased incidence of AD in a co-twin control study (10) and several other clinical studies confirmed a decreased association of AD in individuals treated with anti-inflammatory drugs (11) including COX2 specific inhibitors (12). These findings support the hypothesis that inflammation might contribute to the neurodegeneration associated with AD (13).

In the attempt to better understand the biology of AD the possible role of several cytokines and chemokines has recently been investigated. Virtually all of the mediators analyzed in these studies, including IL-1b, IL-6, TNF- α , IL-8, TGF- β and macrophage inflammatory protein-1a (MIP-1a), have been suggested to be up-regulated in AD compared to non demented controls (14- 18). On the contrary, conflicting results are obtained in relation to the immunomodulatory cytokine IL-10, a type-2 cytokine that suppresses T lymphocytes and cell-mediated immunity in humans and mice and has potent anti-inflammatory properties (19- 21).

These studies considered each cytokine independently as gene polymorphisms and/or production, but never investigated the relationship between factors acting for and against inflammation, such as IL-10 and IL-6, in the same population sample.

It is worth recalling that single nucleotide polymorphisms (SNPs) in the promoter region of these two genes are known. The gene encoding IL-10, mapped to chromosome 1 between 1q31 and 1q32, is highly polymorphic. IL-10 production is correlated to biallelic polymorphisms at positions: -1082 (guanine to adenine substitution), -819 (thymine to cytosine substitution), and -592 (adenine to cytosine substitution). The polymorphism at position -1082 lies within an Ets (E-twenty-six specific)-like recognition site and may affect the binding of this transcriptional factor and therefore alter transcription activation; the -1082 A allele correlates with IL-10 generation after stimulation of T cells *in vitro* (57), while polymorphisms at positions -819 and -592 do not seem to be involved. The IL-6 gene in humans is organised in five exons and four introns and maps to the short arm of chromosome 7 (7p21) (50, 73). The involvement of IL-6 in many biological functions is paralleled by genetic associations of its allelic variants with several physiological and pathophysiological conditions. Two of its polymorphic sites have been frequently used for genetic association studies: a multiallelic variable number of tandem repeats (VNTR) polymorphism in the 3' flanking region (AT repeats) and a biallelic G-to-C polymorphism of the promoter at the position -174. The G/C single nucleotide polymorphism (SNP) seems to be associated with varying blood levels and transcription rates of IL-6 (54, 56, 68).

In the light of these considerations and on the basis of a case-control association study in Italian sporadic late-onset AD patients and matched healthy controls (HC), the present inventors evaluated whether IL-10 and IL-6 SNPs were related with the development of AD. The results shed further light on the inflammatory pathogenic hypothesis of AD and suggest an independent genetic predisposition from the metabolic one.

These allelic variations are associated with measurable differences in IL-10 and IL-6 production by antigen- and mitogen-stimulated peripheral blood lymphocytes. In fact, these polymorphisms occur in the regulatory region of the gene and are associated with high, intermediate or low IL-10 production (22).

The present inventors investigated beta amyloid-stimulated IL-10 and IL-6 production by peripheral blood lymphocytes (PBMC) of AD patients and of age-matched healthy controls. Because the generation of this cytokine was significantly reduced in AD patients, IL-10 polymorphisms were analysed in these same individuals. Results showed that the high IL-10-producing allele is extremely rare in AD patients.

Specifically, IL-10 genotypes are differently distributed when AD are compared with HC ($\chi^2 = 16.007$; $p=0.007$). Therefore genotypes corresponding to reduced IL-10 production have a significantly higher distribution amongst AD subjects (table I). The presence of low-IL-10-producing genotypes is associated with a worsened clinical outcome of AD as follows: 1) earlier age at disease onset (Table II); and 2) faster disease progression (MMSE score)(Table III).

Table I. IL-10 genotype distribution

Genotype (c)	AD n=47	HC n=25	AD %	HC %
GCC/GCC (H)	1	7	2	28
GCC/ACC (M)	10	9	21	36
GCC/ATA (M)	11	3	23	12
ACC/ACC (L)	8	1	17	4
ACC/ATA (L)	12	4	26	16
ATA/ATA (L)	5	1	11	4

The frequency of the different genotypes among Alzheimer's disease patients (AD) are statistically different from those of the healthy controls (HC). $\chi^2 = 16.007$, $df= 5$; $p= 0.007$. In the brackets (c) there are the corresponding phenotype high (H), intermediate (M), low (L).

Table II. IL-10 genotype distribution and age at onset

Genotype	mean	S.D.	SEM
GCC/GCC	76	/	/
GCC/ACC	75.00	8.57	3.03
GCC/ATA	67.33	8.2	2.73
ACC/ACC	76.20	8.79	3.93
ACC/ATA	77.17	4.07	1.66
ATA/ATA	65.75	1.71	0.85

Correlation between the different genotypes in Alzheimer's disease patients and the age at onset. ANOVA: $p = 0.042$.

Table III. IL-10 genotype distribution and MMSE

Genotype	mean	S.D.	SEM
GCC/GCC	18		
GCC/ACC	21.75	5.5	1.94
GCC/ATA	16.33	5.68	1.89
ACC/ACC	10.80	7.5	3.35
ACC/ATA	13.83	5.19	2.12
ATA/ATA	22.5	1.73	0.87

Correlation between the different genotypes in Alzheimer's disease patients and MMSE ANOVA: $p = 0.010$.

Chronic inflammation is suggested to be involved in the neurodegenerative process characteristic of AD (24, 25); this suggestion stems from both *in vivo* and *ex adjuvantibus* criteria. Hence, inflammatory mediators and activated glial cells are observed to be closely associated with neuritic plaques *in vivo*. Furthermore, recent data indicate that anti-inflammatory therapy could be useful in modulating disease progression

(10- 12). Despite this vast body of evidence, the biologic correlates of AD are still unclear. To shed light on this problem, attention was focused on IL-10. This cytokine is a pivotal regulatory cytokine involved in many facets of the immune response and is dysregulated in human autoimmune (26), malignant (27- 31), and infectious (32- 35) diseases. More recently it has been shown that the presence of genetically-determined higher levels of IL-10 secretion is an important component of the genetic background to systemic lupus erythematosus (36) and to the outcome of infectious disease (37). It has also been demonstrated that IL-10 secretion, resulted from *in vitro* stimulation of human peripheral blood leukocytes with LPS, varies markedly between individuals and that cytokine haplotypes are associated with different secretion levels (38). In addition, differences in IL-10 serum production by cells of patients and of their first-degree family members (37, 39), as well as differences in the distribution of IL-10 alleles, suggested the involvement of the different isoforms of the IL-10 gene as an important quantitative trait loci for human disease in infections (37, 40), autoimmune (26, 36, 41, 42) and malignant diseases (43).

The present inventors initially analyzed LPS-, Flu-, and amyloid peptide- specific IL-2 and IL-10 production by peripheral blood mononuclear cells (PBMC) of AD patients and age matched HC. Results showed that: 1) IL-2 production by PBMC of AD patients and controls was similar in all the conditions measured; and 2) IL-10 generation by LPS- and Flu -stimulated PBMC was comparably similar amongst the two groups of individuals. In contrast, an amyloid-specific immune impairment characterized by a reduced generation of IL-10 was present in AD. The observation that this cytokine imbalance was not seen in mitogen-stimulated PBMC indicates that amyloid-specific immune responses are selectively impaired in AD patients. Additionally, results showing that flu-stimulated proliferation was similar in patients and controls indicates that antigenic processing and presentation in association with HLA class II molecules, and the CD4-HLA class II self-restricted pathway of activation of the immune system (44), are not defective in these patients.

Next polymorphisms were analyzed in the IL-10 gene in the same group of subjects. Results stemming from analysis of the distribution of the IL-10 alleles in this Italian sample of healthy individuals showed a close similarity to those reported for other caucasian populations (45). In contrast, we observed a significantly higher frequency of the genotypes corresponding to reduced IL-10 production (ACC/ACC, ACC/ATA and ATA/ATA) in AD patients. Thus, an abnormally augmented prevalence of low-IL-10 producing isoforms in the AD population was determined; the phenotypic correlate of these isoforms becomes evident when amyloid-specific immune responses were measured.

Subsequent analyses focused on possible correlations between impaired IL-10 production and the clinical manifestations of AD by verifying whether the presence of low/intermediate IL-10 producing genotypes would be associated with different disease outcomes. Results confirmed this to be the case. Thus, the presence of the ATA/ATA and of the GCC/ATA genotypes was correlated with an earlier age at disease onset. Additionally, the ACC/ATA and the ACC/ACC (all these are low/intermediate IL-10-producing genotypes) alleles were associated with a more severe cognitive impairment as indicated by a lower MMSE score.

It is interesting to observe that a recent report on Italian centenarians, individuals who - by definition - are less prone to develop age-related diseases, has demonstrated that extreme longevity is associated with a significantly higher frequency of the high IL-10-producing genotypes (46).

IL-10 is known to have potent anti-inflammatory properties (47); a biological scenario could thus be hypothesized in which the reduction of amyloid-specific IL-10 production would favour the triggering of the chronic inflammatory process seen in the progression of AD. These results suggest that an amyloid-specific and IL-10-mediated inhibitory feed-back circuit may be active in non-AD individuals; the rupture of this circuit could be associated with or predictive for the development of AD. Recently, a convincing study showed that an IL-10/pro-inflammatory

circuit that revolves around cells of the innate immune system regulates susceptibility to autoimmune diseases (48). These results are expanded by showing that an alteration of this circuit is present in AD patients.

The present inventors have identified polymorphic regions, which polymorphs are indicative of a dysfunction of cytokine production and hence are associated with a predisposition towards an autoimmune, neurodegenerative or chronic inflammatory disease.

At present, Alzheimer's disease is diagnosed by recognised criteria such as DMS IV or NINCDS-ADRDA (23), often in conjunction with a magnetic resonance image (MRI) or computer aided tomography (CT) scan of the brain to identify the characteristic amyloid plaques and neurofibrillary tangles together with atrophy of the hippocampal area of the brain.

A definitive confirmatory diagnosis of Alzheimer's disease is only possible by a visual inspection of the affected areas of the brain during a post-mortem examination or via brain biopsy (not recommended due to lack of effective therapies).

Therapies and methods for monitoring of Alzheimer's disease are being urgently sought. As the progress is made in efforts to prevent or delay neurodegeneration and disease progression, early detection of Alzheimer's and identification of susceptible patients will gain importance as this will allow preventive measures being employed as early as possible. Therefore a need exists to be able to provide predictive and reliable tests for susceptibility to Alzheimer's disease without the need for lengthy and subjective assessments of cognitive performance.

Accordingly, the present invention provides a method of determining the existence of or a predisposition to Alzheimer's disease, autoimmune disease or other neurodegenerative diseases, the method comprising the steps of taking a DNA bearing sample from a subject animal and analysing the sample to determine the allelic variants present at one or more of the SNP loci at positions -1082, -819 and -592 of the gene encoding IL-10, or to put it another way, analysing the sample for the presence or absence of the alleles of Figure 2.

Preferably, the genotype at all three positions -1082, -819 and -592 is determined.

While the identification of the alleles of Figure 2 has been found to be useful or predictive in the identification of Alzheimer's disease, a combination of the alleles of IL-10 and IL-6 has been found to be more strongly predictive of a predisposition to Alzheimer's or diagnostic of the presence of Alzheimer's disease.

Apolipoprotein E (Apo-E) has been associated with sporadic or non-familial AD. Hence, in a further aspect of the invention, a method of diagnosing Alzheimer's disease comprises the steps of obtaining a DNA-bearing sample from an animal and identifying the presence of a polymorphic allele of IL-10, IL-6 and of Apo-E.

Preferably, the polymorphic allele is one of the alleles of Figure 2.

Additionally, the sample may be assayed for the presence/absence of polymorphisms or other allelic variations of other cytokines in addition to IL-10 and IL-6, for example, IL-10 and IL-6 plus IL-4 and/or IL-1.

Alternatively, the sample may be assayed for the presence of absence of polymorphisms or other allelic variations of IL-10 plus Apo-E, or IL-6 plus Apo-E.

An interleukin 1 alpha (IL-1 alpha) polymorphism has been associated with Alzheimer's disease (77). Hence, in still further aspect of the invention, a method of diagnosing Alzheimer's disease comprises the steps of obtaining a DNA-bearing sample from an animal and identifying the presence of a polymorphic allele of IL-10, IL-6, Apo-E and of IL-1.

Generally, optimal predictive value will be obtained by combining as many predictive factors as possible in the test. The methods described herein together with markers such as Apo-E and IL-1 enable the development of a powerful diagnostic method that would include all the biological markers shown to have a predictive value toward the development of AD.

The invention also provides a method of treating Alzheimer's disease, autoimmune diseases or other neurodegenerative disorders by modulating, that is augmenting or decreasing, the function of a gene having one of the

allelic polymorphisms of IL-10 shown in Table I, or to put it another way, a gene of the allelic polymorphisms of Figure 2.

For example, IL-6 production is preferably downregulated but IL-10 production is preferably upregulated. More preferably, IL-6 production is downregulated simultaneously with IL-10 production being upregulated.

Alternatively, pharmaceutical compositions which inhibit or supply the appropriate cytokines may be administered to a patient in need of treatment. For example, instead of down regulation of IL-6 at a genetic level, a patient may be supplied with compounds which inhibit or block the action of IL-6. This inhibition or blocking may be at the synthesis stage, at the site of action or anywhere along the IL-6 metabolic pathway. Similarly, IL-10 may be supplied directly, as an intermediate, as a pre-cursor or pre-pro-cursor, by stimulating the synthesis of IL-10 *ab initio* or by administration of pharmacological compositions that enhance or inhibit antigen specific production of interleukin-10 and, optionally, one or more other cytokines.

The other cytokine is preferably selected from the group consisting of interleukin-1 (α or β), interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, interferon- α , interferon- β , interferon- γ , TNF- α , TNF- β , G-CSF, GM-CSF, M-CSF, and TGF- β .

Pharmacological agents which can modulate cytokine production are known in the art, for example, heat shock protein (HSP) and/or CpG-motif containing immunomodulatory oligonucleotides. DNA vaccination with constructs encoding the 60-kDa heat shock protein human hsp60 (phsp60) results in increased IL-10 production (71). It has been shown that CpG-DNA can induce the synthesis of suppressor of cytokine signalling (SOC) proteins. CpG-DNA-induced SOC proteins inhibit IL-6 production (72). Additionally, CpG-DNA via the extracellular signal-regulated kinase (ERK) mediated pathway, has been shown to trigger IL-10 production (73). CpG oligonucleotides can be structurally modified to achieve a desired profile of cell types affected and cytokines stimulated; to lean either toward the Th1 (cell

mediated, interferon gamma generating) or Th2 (antibody, IL-10 and IL-4 generating) T helper cell pathway (74). Examples of such diverse modulations are: Th1 profiled compound 7909 generated by Coley Pharmaceuticals and Th2 profiled compounds generated by Dynavax (75). In addition, CpG-like immunomodulatory oligonucleotides in which CpG motif has been substituted with YpG or CpR motifs but which show promise of modification of their immunomodulatory potential via their chemical structure may also be employed as pharmacological agents to affect desired cytokine production profile (76).

In a further aspect, the present invention provides a method of treating Alzheimer's disease in an animal in need of treatment, the method comprising the reduction of IL-6 synthesis simultaneously with the augmentation of IL-10 synthesis.

The invention also provides the use of IL-6 inhibitors and IL-10 promoters in the manufacture of a medicament for the treatment of prophylaxis of Alzheimer's disease.

In a further aspect of the invention DNA fragments and cDNA fragments encoding the allelic polymorphism of Table I, or to put it another way the allelic polymorphisms of Figure 2, for use in the above described method.

These DNA fragments are useful in the screening and identification of compounds which bind to, regulate, or otherwise have a modulatory effect these alleles and hence stimulate or inhibit the synthesis of the gene product.

Accordingly, the present invention further provides a method of screening for compounds which modulate chemokines implicated in Alzheimer's disease, the method comprising introducing the compound to be screened to DNA or cDNA fragments encoding the allelic polymorphisms of Table I, or to put it another way the allelic polymorphisms of Figure 2 and assessing the hybridisation between the compound and the fragment.

Hence, the present invention also provides compounds which modulate Alzheimer's disease, as identified by the above method.

Preferably, the animal is a mammal and more preferably a human being.

The data presented herein support the role of inflammatory processes in the pathogenesis of AD; reinforce the hypothesis that in AD patients neurodegeneration is tightly associated with an aberrant antigen-specific immune response; and lend further support to the use of anti-inflammatory compounds in the therapy of this disease.

Accordingly, in a still further aspect the present invention provides a pharmaceutical composition comprising a cytokine in the preparation of a medicament for the treatment or prophylaxis of disease excluding neoplastic diseases, leukaemias, and acute inflammation. Preferably the disease is a neurodegenerative disorder or an autoimmune disease. Most preferably the disease is selected from the group comprising multiple sclerosis, myasthenia gravis, systemic lupus erythramatosus, diabetes mellitus, asthma, Parkinson's disease, motor neurone disease, Alzheimer's disease, chronic inflammation rheumatoid arthritis, HIV-infection and AIDS.

Preferably, the cytokine is selected from the group consisting of interleukin-1 (α or β), interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, interferon- α , interferon- β , interferon- γ , TNF- α , TNF- β , G-CSF, GM-CSF, M-CSF, and TGF- β , or combinations or mixtures thereof. Preferably, two or more cytokines are used.

Most preferably the or each cytokine is an interleukin, especially interleukin-10 or interleukin-6.

Embodiments of the invention will now be described by way of example only, with reference to the accompanying drawings of which

Figures 1A-1D are bar charts in which show LPS- and β amyloid- (a pool of 3 β amyloid peptides: β A: fragments 25-35; β A: fragment 1-40; and β C: fragment 1-16) stimulated IL-2 (panels A and C) and IL-10 (panels B and D) production by PBMC of 47 AD patients (O) and 25 age- and sex-matched healthy controls (O). Mean values + standard errors are shown. $p \leq 0.023$;

Figure 2 shows paradigmatic example of IL-10 genotyping for six different samples. In each gel the heaviest bands correspond to the amplicons of the human β -globin gene which is used as the internal controls. The other specific amplified DNA fragments correspond to the polymorphisms of the IL-10 gene: GCC/GCC (A), GCC/ACC (B), GCC/ATA (C), ACC/ACC (D), ACC/ATA (E), ATA/ATA (F), and

Figures 3A-3D are bar charts which show LPS- and β -amyloid-stimulated (a pool of three β -amyloid peptides; β A, fragment 25-35; β B, fragment 1-40; and β C, fragment 1-16) production of IL-6 (panels A and C) and IL-10 (panels B and D) by PBMC of 47 AD patients (O) and 25 age- and sex- matched healthy controls (O). Means + standard errors; $p \leq 0.023$.

Example 1

Patients and controls

Forty-seven AD patients and 25 non-demented subjects (HC) were included in a study of Alzheimer's disease. These patients were selected from a larger population sample followed at the Geriatric Department of the Ospedale Maggiore IRCCS, University of Milan, Italy. The DMS IV and NINCDS-ADRDA (23) criteria were adopted to obtain the clinical diagnosis of AD. Cognitive performances and alterations were assessed according to the Mini-Mental State Evaluation (MMSE). AD patients and HC were living at home and were carefully physical examined on the day of blood collection and their clinical records evaluated. In order to minimize the risk of clinical or sub-clinical inflammatory processes, all the patients were selected as follows: only AD and HC without clinical sign of inflammation (e.g. normal body temperature or absence of concomitant inflammatory disease) were included in the study. Blood chemical parameters were also evaluated and subjects with abnormal sedimentation rate of red blood cells or altered blood profile of albumin and transferring plasma levels were excluded. A further selection of AD patients were performed according to the C reactive protein (CRP) plasma

levels and those patients with CRP above 5 mg/l (mean value \pm 2 standard deviations of control values) were not enrolled in the study.

Informed consent to perform the study was obtained from controls and a relative of each AD patient.

Blood sample collection

Whole blood was collected by venipuncture in Vacutainer tubes containing EDTA (Becton Dickinson Co, Rutherford, NJ). Peripheral blood mononuclear cells (PBMC) were separated by centrifugation on lymphocyte separation medium (Organon Teknika Corp., Durham, NC) and washed twice in PBS. The number of viable lymphocytes was determined by trypan blue exclusion and a hemocytometer.

In vitro cytokine production

PBMCs were resuspended at 3×10^6 /ml in RPMI 1640 and were either unstimulated or stimulated with LPS (Sigma, St. Louis, MI) (10 g/ml), with a pool of 3 different peptides from the b-amyloid protein as follows: b-A: fragment 25-35 (25 mg/ml); b-B: fragment 1-40 (150 ng/ml); b-C: fragment 1-16 (150 ng/ml) (Sigma, St. Louis, MI); or with influenza virus vaccine (A/Taiwan+A/Shanghai+B/Victoria) (24 g/l; final dilution 1:1000) (Flu) (control antigen) at 37°C in a moist, 7% CO₂ atmosphere. Supernatants were harvested after 48 hours for LPS stimulation and after 5 days of culture for the b-amyloid protein peptides and Flu. Production of IL-2 and IL-10 by PBMCs was evaluated with commercial available ELISA kits (ACCUCYTE, Cytimmune Sciences, Inc, College Park, MD). All test kits were used following the procedures suggested by the manufacturer.

IL-10 genotyping

Genomic DNA was extracted from EDTA-treated peripheral blood (10 ml) using a standard proteinase K and phenol/chloroform method. The DNA concentration and purity were determined by spectrophotometric analysis. A polymerase chain reaction-sequence specific primers (PCR-SSP)

methodology was utilised to assess the IL-10 genotypes. The amplification of the sequence in the promoter region of the IL-10 (polymorphic positions -1082, -819, -592) gene were performed using the Cytokine genotyping Tray Method (One Lambda, Canoga Park, CA, USA); the human β -globin gene was amplified as an internal control of genomic DNA preparation. PCR condition were indicated by One Lambda PCR program (OLI-1); the PCR products were then visualised by electrophoresis in 2.5% agarose gel.

Statistical analysis

Statistical analysis was conducted using SPSS statistical package (SPSS, Chicago, IL). Differences in IL-10 production stemmed from analytic procedures based on non parametric analyses (Mann-Whitney); comparisons between different groups of patients were made using Fisher's exact 2-tailed test. Genotype frequencies were compared between the study groups by χ^2 test with an observed significance level of the test below 0.05. Comparisons between the mean values of the age at onset and MMSE in the six different groups of AD were performed by one-way ANOVA analysis.

Age, gender and MMSE scores in AD patients and in HC

Forty-seven AD patients and 25 age-matched healthy controls were enrolled in the study. The Mini-Mental State Evaluation (MMSE) showed the presence of a mild-to-severe cognitive deterioration in the AD patients. These data are shown in Table I.

MBP-stimulated IL-10 production is reduced in AD patients

PBMC of 47 AD patients and of 25 age- and sex-matched HC were stimulated with a mitogen (LPS); a pool of 3 amyloid peptides (A: fragment 25-35, B: fragment 1-40, and C: fragment 1-16) (amyloid), or Flu (used as a control antigen) and the production of IL-2 and IL-10 was measured with ELISA methods. No differences were seen when LPS- or Flu-stimulated IL-2 and IL-10 production was compared in AD patients and HC. amyloid-stimulated IL-2-production was also similar in the two groups of individuals

studied. In contrast with these results, amyloid-stimulated production of IL-10 was significantly reduced ($p=0.023$) in AD patients compared to controls. These data are shown in Figure 1.

The distribution of high, intermediate, and low IL-10 producing genotypes is skewed in AD patients

Paradigmatic example of the six different IL-10 genotypes, evaluated by PCR-SSP, is showed in Fig. 2 and their relative distribution among a typical Caucasian population sample is shown in Table II. In contrast with the distribution observed in HC, the frequency of the different IL-10 genotypes among AD patients was significantly skewed ($\chi^2 = 16.007$ with $p=0.007$) (Table II). Therefore genotypes corresponding to reduced IL-10 production (ACC/ACC, ACC/ATA and ATA/ATA genotypes) had a significantly higher distribution amongst AD subjects (17%, 26% and 11% respectively versus 4%, 16% and 4% in HC). Moreover the GCC/ACC to GCC/ATA ratio (intermediate phenotype) was 1:1 in AD while was 3:1 in HC.

Low IL-10 production is correlated with worsened clinical outcome of AD

To analyse possible clinical correlates of the presence of low IL-10 genotype, we subsequently examined the six genotypes in relation to age of AD onset (Table III) and the progression of cognitive deterioration (Table IV). The results confirmed that the presence of low-IL-10-producing genotypes is indeed associated with a worsened clinical outcome of AD. Thus, presence of the ATA/ATA and GCC/ATA genotypes was associated with an earlier age at disease onset (ANOVA: $p=0.042$)(Table III); additionally, an inverse correlation was detected between ACC/ATA and ACC/ACC, low IL-10-producing genotypes, and the MMSE score (ANOVA: $p=0.010$)(Table IV).

Table IV. Genetic Association Data for Autoimmune/Inflammatory Disease
www.grc.nia.nih.gov/branches/rrb/dna/geneticdata.htm

Chrom	CH-band	Gene	Disease	Allele	P-value	Reference	PubMedID
1	1q31.1	CD45	Ms	C to G in position 77 of PTPRC exon 4.	P=1.510-4	Jacobsen M 00	11101853
1	1q31.1	CD45	SCId	deletion	na	Kung C 00	10700239
	Mouse	CD45	autoimmune nephritis	glutamate 613 to arginine	na	Majeti R 00	11163182
1	1q32.1	IL10	SLE	-4kb to 5'	P=.0001	Gibson AW 01	11238636
1	1q32.1	IL10	SS	-10 GCC haplotype (G -1082, C -819, and C -592 of the IL-10 gene	P=<0.05	Hulkkonen J 01	11212157
1	1q32.1	IL10	RA	genotype -1082GG	P=<0.03	Huizinga TW 00	11085795
1	1q32.1	IL10	RA	ATA haplotype, pts w/>4 joints	P=0.02	Crawley E 99	10366102
1	1q32.1	IL10	GVHD	IL-10 (-)1064	P=<.001	Middleton PG 98	9808588
1	1q32.1	IL10	IBD/UC	-1082*G allele (high producer) was reduced in pts	P=0.03	Tagore A 99	10551422

2	2q12.2	IL1RA	SLE	IL1RN*2 allele	na	Blakemore AL 94	7945503
2	2q12.2	IL1RA	Ulcerative Colitis	IL1RN*2 allele	P=0.007	Mansfield JC 94	8119534
2	2q12.2	IL1RA	polymyalgia rheumatica	IL1RN*2 allele	na	Boiardi L 00	11138328
2	2q33.1	CTLA4	RA	A/G 49	P=0.009	Gonzalez MF 99	10203024
2	2q33.1	CTLA4	GD	A/G 49	P=<0.01	Yanagawa T 97	9459626
2	2q33.1	CTLA4	MS	A/G 49	P=0.006	Harbo HF 99	10082437
2	2q33.1	CTLA4	H-Thy	A/G 49	P=<0.03	Donner H 97	9398726
2	2q33.1	CTLA4	IDDM	A/G 49	P=0.004	Takahiro A 99	
2	2q33.1	CTLA4	IDDM		na	Yanagawa T 99	10052685
2	2q33.1	CTLA4	IDDM	A/G 49	P=0.00002	Marron MP 97	9259273
5	5q31.1	IL4	GD	position 590 allele reduced in GD	P=0.00004	Hunt PJ 00	10843185
5	5q31.1	IL4	increased IgE	C+33T polymorphism with elevated total serum IgE	P=<0.05	Suzuki I 00	11122213
5	5q31.1	IL4	asthma, FEV(1)	C-589T IL-4 promoter genotype (TT)	P=0.013	Burchard EG 99	10471619

5	5q31.1	IL4	AD	-590C/T	P=0.001	Kawashima T 98	9643293
5	5q31.1	IL4	RA	IL-4(2) higher in non-destructive RA	P=0.0006	Buchs N 00	11035134
5	5q31.1	IL4	MS	IL-4 B1 allele, late onset MS	P=<0.001	Vandenbroeck K 97	9184650
5	5q31.1	IL13	asthma	Gln110Arg	P=0.017	Heinzmann A 00	10699178
5	5q31.1	IL13	asthma	C to T at position -1055 (TT)	P=0.002	van der Pouw Kraan TC 99	11197307
6	6p21.31	TNFA	asthma	G/A -308 TNF2	P=0.003	Albuquerque R 98	9645594
6	6p21.31	TNFA	PrimBiCirr	G/A -308 TNF1	P=0.02	Gordon M 99	10453936
6	6p21.31	TNFA	Sepsis	G/A -308 TNF2	P=0.007	Majetschak M 99	10450735
6	6p21.31	TNFA	Psoriasis	G/A -308 TNF1	P=2.74 X 10 -8	Arias A 97	9395887
6	6p21.31	TNFA	lep. Leprosy	G/A -308 TNFd	P=.02	Roy S 97	9237725
6	6p21.31	TNFA	GVHD	G/A -308 TNF1	P=.006	Middleton PG 98	9808588
6	6p21.31	TNFA	Silicosis	G/A -308 TNF1	P=<0.05	Yucesoy B 01	11264025
6	6p21.31	TNFA	SLE	G/A -308 TNF1	na	Sullivan KE 97	9416858
6	6p21.31	TNFA	celiac	G/A -308 TNF1	P=<0.001	McManus R 96	8655356

6	6p21.31	TNFA	chronic bronchitis	G/A -308 TNF1	P=<0.01	Huang S 97	9372657
6	6p21.31	TNFA	Psoriasis	-238 TNF1	P=1.64 X 10 ⁻⁷	Arias A 97	9395887
7	7p15.3	IL6	IDDM	G, G(-174) increased in pts	P=<0.002	Jahromi MM 00	11054276
7	7p15.3	IL6	SLE	AT-rich minisatellite in 3' flanking region	P=0.001	Linker-Israeli M 99	11197305
7	7p15.3	IL6	RA	622 and -174 alleles, age of onset	na	Pascual M 00	11196696
7	7p15.3	IL6	MS	carriage larger alleles A6-->A9, accelerated onset	P=0.025		
12	12q12	VDR	GD	exon 2 initiation codon (VDR-FOK:I) polymorphism	P=0.023	Ban Y 00	11134121
12	12q12	VDR	RA	BB/ft genotype	na	Garcia-Lozano JR 01	11251690
12	12q12	VDR	MS	bb	P=0.0263	Fukazawa T 00	10465499
12	12q12	VDR	CD	tt	P=0.017	Simmons JD 00	10896912
12	12q12	VDR	IDDM	Bsml	P=0.015	Chang TJ 00	10792336

12	12q21.1	IFNG	asthma	CA repeat polymorphism within the first intron	P=0.0018	Nakao F 01	11240951
12	12q21.1	IFNG	IDDM	CA repeat polymorphism within the first intron	P=0.039	Awata T 94	7867888
12	12q21.1	IFNG	GD	CA repeat polymorphism within the first intron	P=<0.04	Siegmund T 98	9848715
12	12q21.1	IFNG	RA	CA repeat polymorphism within the first intron	P=<0.0001	Khani-Hanjani A 00	11022930
16	16p11.1	IL4R	asthma	Ile50Val	P=<0.0001	Mitsuyasu H 98	9620765
16	16p11.1	IL4R	hyper-IgE syndrome and severe eczema, atopy	Arg576G	P=0.001	Hershey GKK 97	9392697
16	16p11.1	IL4R	MS(PPMS)	IL4R variant R551	P=0.001	Hackstein H 01	11164908

[DNA Array Unit] [IRP Home] [NIA Home]

Example 2

Patients and controls

Sixty-five AD patients (44 F/21 M, mean age 80 ± 2) and 65 non-demented sex- and age- matched healthy controls (HC) were enrolled. The patients were selected from a larger population sample followed at the Geriatric Department of the Ospedale Maggiore IRCCS, University of Milan, Italy. We applied the DMS IV and NINCDS-ADRDA (23) criteria to obtain the clinical diagnosis of AD; every subject had a recent brain magnetic resonance imaging (MRI)/computed tomography (CT) scan available. Cognitive performances and alterations were assessed according to the Mini-Mental State Evaluation (MMSE). AD patients and HC were living at home and a careful physical examination was done on the day of blood collection, and their clinical records were consulted.

In order to minimize the risk of clinical or sub-clinical inflammatory processes, subjects were selected as follows: only AD and HC without clinical signs of inflammation (e.g. normal body temperature, no concomitant inflammatory condition) were eligible. Blood chemistry tests were done and subjects with an abnormal red blood cell sedimentation rate or altered albumin and transferring plasma levels were excluded. AD patients were further selected according to their C reactive protein (CRP) plasma levels and any with CRP above 5 mg/L (mean + 2 standard deviations of control values) were not eligible.

Informed consent was obtained from all the subjects or their relatives. The study protocol was approved by the Ethics Committee of the University Hospital.

Blood sampling

Whole blood was collected by venipuncture in Vacutainer tubes containing EDTA (Becton Dickinson Co., Rutherford, NJ). Peripheral blood mononuclear cells (PBMC) were separated by centrifugation on lymphocyte separation medium (Organon Teknika Corp., Durham, NC) and washed twice in PBS. Viable lymphocytes were counted by Trypan blue exclusion and a

hemocytometer.

Genotyping

Genomic DNA was extracted using a standard proteinase K and phenol/chloroform method. The DNA concentration and purity were determined by spectrophotometric analysis. A polymerase chain reaction-sequence-specific primers (PCR-SSP) method was utilised to assess IL-10 and IL-6 genotypes. The sequence in the promoter region of the IL-10 (polymorphic positions -1082, -819, -592) and IL-6 (polymorphic position -174) genes was amplified using the cytokine genotyping tray method (One Lambda, Canoga Park, CA, USA); the human β -globin gene was amplified as an internal control for the genomic DNA preparation. PCR conditions were indicated by the One Lambda PCR program (OLI-1) and the PCR products were visualised by electrophoresis in 2.5% agarose gel.

The ApoE genotypes were determined by PCR amplification of a 234 base-pair fragment of exon 4 of the ApoE gene, followed by digestion with Cfo1. The restriction patterns were obtained by gel electrophoresis.

In vitro cytokine production

PBMCs were resuspended at $3 \times 10^6/\text{mL}$ in RPMI 1640 and were either unstimulated or stimulated with LPS (Sigma, St. Louis, MI) ($10 \mu\text{g}/\text{mL}$), with a pool of three peptides from the β -amyloid protein as follows: β -A, fragment 25-35 ($25 \text{ ng}/\text{mL}$); β -B, fragment 1-40 ($150 \text{ ng}/\text{mL}$); β -C, fragment 1-16 ($150 \text{ ng}/\text{mL}$)(Sigma), or with influenza virus vaccine (A/Taiwan+A/Shanghai+B/Victoria) ($24 \mu\text{g}/\text{L}$; final dilution 1:1000) (Flu) (control antigen) at 37°C in a moist, 7% CO_2 atmosphere. Supernatants were harvested after 48 hours for LPS stimulation and after five days of culture for the β -amyloid protein peptides. Production of IL-10 and IL-6 by PBMCs was evaluated with commercial ELISA kits (ACCUCYTE, Cytimmune Sciences Inc., College Park, MD). All test kits were used following the manufacturer's directions.

Statistical analysis

Statistical analysis was done using the SPSS statistical package (SPSS, Chicago, IL). Genotype frequencies were compared in the study groups by the χ^2 test with a level of significance below 0.05. The odds ratio (OR) and 95% confidence intervals (CI) were also calculated. Adjusted ORs were estimated by logistic regression, controlling for ApoE 4 carrier status. Homogeneity of the ORs between strata was assessed by including the appropriate interaction terms in the model. Differences in IL-10 and IL-6 production were established by procedures based on non-parametric analysis (Mann-Whitney); different groups of patients were compared using Fisher's exact two-tailed test.

The distribution of high, intermediate, and low IL-10 producing genotypes is skewed in AD patients

The genotype and allele frequencies of the biallelic polymorphism at position -1082 are reported in Table V. This SNP alters transcriptional activation with a gene dosage-related effect, so GG genotype correlates with high, GA with intermediate and AA with low IL-10 production after stimulation of T cells *in vitro* (57). AD patients show a significantly higher frequency of the -1082A low producer allele, which skews the genotype distribution in AD compared to HC with a significant decrease of -1082GG high producer genotype (Table V).

Table V. Frequency of the different IL-10 genotypes and alleles observed in Alzheimer's disease patients (AD) and in healthy age-matched controls.

	Genotype			Allele	
	G/G (H) ^a	G/A (M)	A/A (L)	A	G
AD	4 (6.4%)	28 (44.4%)	31 (49.2%)	90 (71.4%)	36 (28.6%)
HC	14 (22.2%)	29 (46%)	20 (31.8%)	69 (54.8%)	57 (45.2%)

^a The corresponding phenotypes: high (H), intermediate (M), low (L) are shown in brackets

Genotype: $\chi^2 = 7.946$, df= 2, p= 0.019

Allele: $\chi^2 = 6.817$, df= 1, p= 0.009

The some SNP is linked with two other SNPs at positions -819 and -592. They combine with microsatellite alleles to form haplotypes where the difference in IL-10 production is mainly accounted for by the -1082 SNP (38, 42). The genotype and allele frequencies of -819 C→T and -592 C→A SNPs were distributed similarly in our AD and HC samples (data not shown).

The -174C allele in the IL-6 gene is over-represented in AD patients

The distribution of IL-6 genotypes and alleles in HC and AD is shown in Table 6. This functional polymorphism also seemed related to the plasma IL-6 concentration; however, it is not clear how this SNP influences IL-6 plasma levels (54). The results of the genotype distribution in our AD and HC samples, with a lower frequency of GG genotype in AD patients. Similarly, the allele distribution was significantly different in the two groups, the C allele being significantly higher in AD (Table VI).

Table VI. Frequency of the different IL-6 genotypes and alleles observed in Alzheimer's disease patients (AD) and in healthy age-matched controls.

	Genotype			Allele	
	G/G (H) ^a	G/C (H)	C/C (L)	C	G
AD	17 (29%)	34 (57.6%)	8 (13.4%)	50 (42.4%)	68 (57.6%)
HC	32 (50%)	27 (42.2%)	5 (7.8%)	37 (28.9%)	91 (71.1%)

^a High (H) and low (L) phenotypes are in brackets

Genotype: $\chi^2 = 5.894$, df= 2 , p= 0.052

Allele: $\chi^2 = 4.300$, df= 1 , p= 0.038

L-10 and IL-6 allele combination and relative risk of developing AD

We investigated whether any combination of the IL-10 GA and IL-6 GC alleles affected the risk of AD. The concomitant presence of both IL-10 A and IL-6 C alleles significantly raised this risk, independently of the ApoE4 status (Table VII). The IL-10 A/A genotype alone or the IL-6 C/C genotype alone both conferred a smaller increase in the risk of the disease (OR 5.8, CI 1.7-20, p=0.005; OR 3.0, CI 0.9-10.6, p=0.087).

Table VII. IL-10 and IL-6 alleles and risk for Alzheimer disease

IL-10	IL-6	OR	95% CI	adj. OR	95% CI
G allele	G allele	1		1	
G	C	2.8	0.2-40	0.9	0.1-26.5
A	G	4.6	0.5-41	3.3	0.3-36.3
A	C	11.2*	1.3-97.3	10.3*	1.0-108

* $p > 0.05$;

OR: crude odds ratio; adj. OR: apolipoprotein E $\epsilon 4$ adjusted odds ratio;

CI: confidence interval

LPS, Flu, and amyloid peptide-stimulated IL-10 and IL-6 production is reduced in AD patients

PBMC of 47 AD patients and 25 age- and sex-matched HC were stimulated with a mitogen (LPS), with a pool of three β amyloid peptides (βA , fragment 25-35; βB , fragment 1-40; βC , fragment 1-16), or with Flu and the production of IL-10, IL-6 was measured with ELISA methods. There were no differences in LPS- or flu- stimulated IL-6 and IL-10 production in AD and HC. In contrast, when β -amyloid-stimulated production of IL-6 and IL-10 was analysed, a marginal increased IL-6 production and a significant decrement of IL-10 generation ($p = 0.023$) were seen in AD patients compared to HC, suggesting an antigen-specific impairment in the production of these cytokines. These data are shown in Figure 3.

The causative role of chronic inflammation in the pathogenesis of AD is still mainly speculative (24, 25). Nonetheless a "cytokine cycle" has been proposed where (19) the anti-inflammatory cytokines (IL-4, IL-10 and IL-13) regulate β -amyloid-induced microglial/macrophage inflammatory responses and modify the microglial activity surrounding amyloid neuritic plaques (52).

These cytokines can inhibit the induction of IL-1, TNF- α and MCP-1 in differentiated human monocytes and, above all, IL-10 causes dose-dependent inhibition of the IL-6 secretion induced by β -amyloid in these cells and in murine microglia (19).

From a clinical point of view, IL-10 is involved in autoimmune diseases (41, 42, 26) and in malignancies (31, 27, 43) where the higher levels of the cytokine depend on genetic background (59) but also influence the outcome of infections (34, 40, 37).

More consistent is the evidence of a role of IL-6 in the pathogenesis of AD. Elevated IL-6 immunoreactivity was observed close to amyloid plaques in the brain of these patients (67); IL-6 induces the synthesis of β -amyloid precursor protein (69), and in transgenic mouse models elevated CNS levels of IL-6 result in neuropathogenic effects and cognitive deficits (51).

The C allele of a VNTR on the IL-6 gene was reported to reduce cytokine activity (61). The IL-6 VNTR C allele has been correlated with a delayed initial onset and reduced AD risk in a German population (63). The functional polymorphism -178 of the promoter region could also be involved in the development of AD phenotype because of its association with plasma concentrations of the cytokine (54). However, in two clinical sets of different ethnic origin the results were debatable (49).

In our sample the data from SNP analysis showed HC had a distribution of IL-10 and IL-6 alleles similar to that of an Italian population (65). More importantly, the present results point to a significantly higher percentage of IL-10 -1082A carriers among AD cases. A recent report on Italian centenarians, who are clearly less prone than younger persons to age-related diseases, showed that extreme longevity is significantly associated with the high IL-10-producing genotypes (58).

As we have previously reported, the results on IL-6 SNPs are more contradictory. The IL-6 G allele seems significantly in AD of Japanese (66) and also of southern Italian origin (64), whereas in our sample it is the C allele that appears over-represented.

To link these differing findings several points have to be considered.

Ethnicity may strongly influence the role of genetic risk factors, and so may the distribution of gene variants in the populations of different European countries, or even among different areas of the same country (53, 55, 60, 62, 70). In addition, the association between AD and IL-6 SNPs may be confined to particular ages, and in our samples AD and HC subjects were all old-old.

Finally, we must considered the role played by a gene or by several genes in linkage disequilibrium with this mutation: a strong disequilibrium between -174 SNP and the VNTR polymorphism of the 3' flanking region of the IL-6 gene has been described in Germans (49).

The main finding of this study was the identification of a group of subjects with a high risk of late-onset AD on account of the concomitant presence of IL-10 -1082A and IL-6 -174C alleles. We also explored interactions between Apo E and IL-10 or IL-6 genes but did not find any evidence of synergistic effects, suggesting that these inflammation- related alleles are an additional and independent risk factor for AD.

To shed more light on the genetic results, the inventors also analysed β -amyloid peptide-, LPS-, and Flu-specific IL-10 and IL-6 production by peripheral blood mononuclear cells (PBMC) in a subset of AD patients and age-matched HC. The results showed that: 1) IL-6 production by PBMC of AD patients and controls did not differ significantly in any conditions; and 2) IL-10 generation by LPS- and Flu-stimulated PBMC was comparable in the two groups, whereas a β -amyloid-specific immune impairment characterized by a reduced generation of IL-10 was noted in AD. The fact that this cytokine imbalance was not seen in mitogen-stimulated PBMC indicates that β -amyloid-specific immune responses are selectively impaired in AD. Additionally, the finding that flu-stimulated proliferation was similar in patients and controls indicates that antigenic processing and presentation in association with HLA class II molecules, and the CD4-HLA class II self-restricted pathway of activation of the immune system (44), are not defective in AD. Thus a biological scenario is conceivable in which the reduction of amyloid-specific IL-10 production favours the triggering of the chronic

inflammatory process seen in the AD brain. An amyloid-specific and IL-10-mediated inhibitory feedback circuit could be active in non-AD individuals, and a breakdown of this circuit could be associated with, or predictive of, the development of AD. A recent study showed convincingly that an IL-10/pro-inflammatory circuit revolving around cells of the innate immune system regulates susceptibility to autoimmune diseases (48). Our results extend this concept by showing that in AD patients this circuit is altered. The data as a whole support the theory that the overall risk of developing AD may be governed by a "susceptibility profile", that reflects the combined influence of inheriting multiple high-risk alleles, and casts light on the pivotal role of IL-10 and IL-6 SNPs in this profile.

Inflammation is involved in the pathogenesis of Alzheimer's disease (AD, the anti-inflammatory cytokine interleukin-10 (IL-10) might counteract IL-6 activity in the brain. As the promoter of these genes is polymorphic, the 65 AD patients and 65 healthy controls (HC) the present investigated the IL-10 -1082 GA and IL-6 -174 GC alleles. In several cases they also assessed IL-10 and IL-6 production by PBMC. For IL-10 there was a significant higher level of the -1082GG genotype ($p=0.019$) in HD than HC, while for IL-6 the G/G genotype was lower and the C allele higher ($p<0.005$). The concomitance of IL-10 A and IL-6 C alleles significantly raised the risk of AD (odds ratio: OR 11.2, confidence interval: CI 1.3-97.3; $p<0.05$) independently of ApoE4 (adjusted OR 10.3, CI 1-108; $p<0.05$). Only amyloid-stimulated IL-10 production differed in AD and HC ($p=0.023$). These results conflict with the inflammatory theory in AD, pointing to a pivotal role of IL-10 and IL-6 polymorphisms and a selective alternation in this network.

Example 3

Genotype analyses on interferon- γ and TNF- α

The methods described in the preceding Examples were used to perform genotype analysis on interferon- γ and TNF- α in Alzheimer's patients and healthy controls. A summary of the results is shown in tables VIII and IX.

Table VIII. IFN- γ genotype distribution

	Genotype (c)			Allele	
	T/T (H)	T/A (I)	A/A (L)	T	A
AD	11(15.5%)	35(49.3%)	25(35.2%)	57(40%)	85(60%)
HC	11(18%)	31(51%)	19(31%)	53(43%)	69(57%)

The frequencies of the different genotypes among Alzheimer's disease patients (AD) were not statistically different from those of the health controls (HC).

$$\chi^2 = 0.305, \text{ df} = 2, \text{ p} = 0.859.$$

In the brackets (c) there are the corresponding phenotype high (H), intermediate (M) and low (L).

Allele:

$$\chi^2 = 0.174, \text{ df} = 1, \text{ p} = 0.676.$$

Table IX. TNF- α genotype distribution

	Genotype			Allele	
	G/G (L) ^a	G/A (H)	A/A (H)	C	G
AD	60 (82%)	12 (16.5%)	1 (1.5%)	132 (90%)	14 (10%)
HC	32 (69%)	13 (28%)	1 (3%)	77 (84%)	15 (16%)

The frequencies of the different genotypes among Alzheimer's disease patients (AD) were not statistically different from those of the health controls (HC)

^a High (H) and low (L) phenotypes are in brackets

$$\text{Genotype: } \chi^2 = 2.568, \text{ df} = 2, \text{ p} = 0.277$$

$$\text{Allele: } \chi^2 = 1.792, \text{ df} = 1, \text{ p} = 0.181$$

There are no statistically significant differences when Alzheimer's patients and controls are compared indicating that neither interferon- γ nor TNF- α is associated with the likelihood of developing Alzheimer's disease.

In contrast, the present invention shows that IL-10 and IL-6 are highly predictive for developing Alzheimer and possibly also predict disease progression. The best predictive value will be achieved by combining genotype tests for multiple gene polymorphisms e.g. IL10, IL-6, Apo-E and others shown to be associated with Alzheimer's disease.

References

1. Ernst, R.L. and J.W. Hay. 1994. The US economic and social costs of Alzheimer's disease revised. *Am. J. Public Health*. 84: 1261.
2. Goate, A., M.C. Chartier-Harlin, M. Mullan, J. Brown, F. Crawford, L. Fidani, L. Giuffra, A. Haynes, N. Irving, L. James, R. Mant, P. Newton, K. Rook, P. Roques, C. Talbot, M. Pericak-Vance, A. Roses, R. Williamson, M. Rossor, M. Owen and J. Hardy. 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 349: 704.
3. Levy-Lahad, E., W. Wasco, P. Poorkaj, D.M. Romano, J. Oshima, W.H. Pettingell, C.E. Yu, P.D. Jondro, S.D. Schmidt, K. Wang, A.C. Crowley, Y.H. Fu, S.Y. Guenette, D. Galas, E. Nemens, E.M. Wiisman, T.D. Bird, G.D. Schelleberg and R.E. Tanzi. 1995. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science*. 269: 973.
4. Sherrington, R., E.I. Rogaev, Y. Liang, E.A. Rogaeva, G. Levesque, M. Uveda, H. Chi, C. Lin, G. Li, K. Holman, T. Tsuda, L. Mar, J.F. Fonci, A.C. Bruni, M.P. Montesi, S. sorbi, I. Rainero, L. Pinessi, L. Nee, I. Chumaken, D. Pollen, A. Brookes, P. Sanseau, R.J. Polinsky, W. Wasco, H.A.R. Da Silva, J.L. Haines, M.A. Pericak-Vance R.E. Tanzi, A.D. Roses, P.E. Fraser, J.M. Rommens and P.H. George-Hyslop. 1995. Cloning of a gene bearing missense mutation in early-onset familial Alzheimer's disease. *Nature*. 375: 754.
5. Blacker, D., J.L. Haines, L. Rodes, H. Terwedow, R.C.P. Go, L.E. Harrel, R.T. Perry, S.S. Basset, G. Chase, D. Meyers, M.S. Albert and R. Tanzi. 1997. ApoE-4 and age at onset of Alzheimer's disease: The NINH Genetics Initiative. *Neurology*. 48: 139.

6. Poirier, J., J. Davignon, D. Bouthillier, S. Kogan, p. Bertrand and S. Gauthier. 1993. Apolipoprotein E polymorphism and Alzheimer's disease. *Lancet*. 342: 697.
7. Saunders, A.M., W.J. Strittmatter, D. Schmechel, P.H. George-Hyslop, M.A. Pericak-Vance, S.H. Joo, B.L. Rosi, J.F. Gusella, D.R. Crapper-MacLachlan and M.J. Alberts. 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology*. 43:1467.
8. Fassbender, K., C. Masters and K. Beyreuther. 2000. Alzheimer's disease: an inflammatory disease?. *Neurobiology of Aging*. 21: 433.
9. McGeer, P.L. and E.G. McGeer. 2001. Inflammation, autotoxicity and Alzheimer disease. *Neurobiology of Aging*. 22: 799.
10. Zandi, P.P and J.C.S. Breitner. 2001. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. *Neurobiology of Aging*. 22: 811.
11. Rogers, J., L.C: Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, A.W. KasniaK, j. Zalinski, M. Cofield, L. Mansukhani, and P. Willson. 1993. Clinical trial of indomethacin in Alzheimer's disease. *Neurology*. 43: 1609.
12. Hauss-Wegrzyniak, B., L.B. Willard, P. Del Soldato, G. Pepeu and G.L. Wenk. 1999. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. *Brain Res*. 815: 36.
13. Neuroinflammation Working Group. 2000. Inflammation and Alzheimer's disease. *Neurobiology of Aging*. 21: 383.

14. Licastro, F., S. Pedrini, L. Caputo, G. Annoni, L.J. Davis, C. Ferri, V. Casadei and L.M.E. Grimaldi. 2000. Increased plasma levels of interleukin-1, interleukin-6 and α -1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from brain?. *Journal of Neuroimmunology*. 103: 97.
15. Mrak, R.E. and W.S.T. Griffin. 2001. Interleukin-1, neuroinflammation, and Alzheimer's disease. *Neurobiology of Aging*. 22: 903.
16. Perry, R.T., J.S. Collins, H. Wiener, R. Acton and R.C.P. Go. 2001. The role of TNF and its receptors in Alzheimer's disease. *Neurobiology of Aging*. 22: 873.
17. Wyss-Coray, T., E. Masliah, M. Mallory, L. McConlogue, K. Johnson-Wood, C. Lin and L. Mucke. 1997. Amyloidogenic role of cytokine TGF- β 1 in transgenic mice and in Alzheimer's disease. *Nature*. 389: 603.
18. Meda, L., P. Baron, E. Prat, E. Scarpini, R. Delgado, A. Catania, J.M. Lipton and G. Scarlato. 1999. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid. *J. Immunol.* 93: 45.
19. Szczepanik, A.M., S. Funes, W. Petko and G.E. Ringheim. 2001. IL-4, IL-10 and IL-13 modulate A β (1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. *J. Neuroimmunol.* 113: 49.
20. Lombardi, V.R., M. Garcia, L. Rey and R. Cacabelos. 1999. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD). *J. Immunol.* 97: 163.

21. Engelborghs, S., M. De Brabander, J. De Cree, R. D'Hooge, H. Geerts, H. Verhaegen and P.P. De Deyn. 1999. Unchanged levels of interleukins, neopterin, interferon-gamma and tumour necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. *34*: 523.
22. Hutchinson, I.V., V. Pravica and P.J. Sinnot . 1998. Genetic regulation of cytokine synthesis: consequences or acute and chronic organ allograft rejection. *Graft*. 1: 15.
23. McKhann, G., D. Drachman, M. Folstein, R. Katzman, D. Proce, E.M. Stadlan. 1984. Clinical diagnosis of Alzheimer's disease. *Neurology*. 34: 939.
24. Eikelenboom, P., S.S. Zhan, W.A. van Goll and D. Allsop D. 1994. Inflammatory mechanisms in Alzheimer disease. *Trends Pharmacol Sci* 15:447.
25. Rogers, J., S. Webster, and L.F. Lue. 1996. Inflammation and Alzheimer's disease pathogenesis. *Neurobiol Aging* 17:686.
26. Llorente, L., W. Zou, Y. Levy, Y. Richaud-Patin, Y. Wijdenes, J. Alcocer-Varela, B. Morel-Fourrier, J.C. Brouet, D. Alarcon-Segovia, P. Galanaud. 1995. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. *J. Exp. Med.* 181: 839.
27. Luscher, U., L. Filgueira, A. Juretic, M.Zuber, L.J. Luuscher, M. Heberer and g.C. Spagnoli. 1994. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. *Int. J. Cancer*. 57: 612.

28. Matsuda, M., F. Slazar, M. Petersson, G. Masucci, J. Hansson, Q.C. Zhang, M.G. Masucci and R. Kiessling. 1994. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. *J. Exp. Med.* 180: 2371.
29. Kim, J., R.L. Modlin, R.L. Moy, S.M. Dubinett, T. McHugh, B.J. Nickloff and K. Uyumura. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. *J. Immunol.* 155: 2240.
30. Suzuki, T., H. Tahara, S. Narula, K.W. Moore, P.D. Robbins, and M.T. Lotze. 1995. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogenic and syngenic tumors. *J. Exp. Med.* 182: 447.
31. Fortis, C., M. Foppoli, L. Gianotti, L. Galli, G. Citterio, G. Consogno, O. Gentilini and M. Braga. 1996. Increased interleukin-10 serum levels in patients with solid tumours. *Cancer Lett.* 104: 1.
32. Murray, P.J., L. Wang, R.C. Onufry, R.I. Tepper, and R.A. Young. 1997. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. *J. Immunol.* 158: 315.
33. Lehmann, A.K., A. Halstenen, S. Sornes, O. Rokke and A. Waage. 1995. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. *Infect. Immun.* 63: 2109.
34. Clerici, M., T.A. Wynn, J.A. Berzofsky, R.L. Coffman, A. Sher, G.M. Shearer. 1994. Role of Interleukin-10 (IL-10) in T Helper Cell Dysfunction in Asymptomatic Individuals Infected with the Human Immunodeficiency Virus (HIV-1). *J. Clin. Invest.* 93:768.

35. VanFurth, A.M., E.M. Seijmonsbergen, J.A.M. Langermans, P.H.P. Groeneveld, C.E. Debel and R. VanFurth. 1995. High levels of interleukin 10 and tumor necrosis factor alpha in cerebrospinal fluid during the onset of bacterial meningite. *Clin. Infect. Dis.* 21: 220.
36. Llorente, L., Y. Richaud-Patin, J. Couderc, D. Alarcon-Segovia, R. Ruiz-Soto, N. Alcocer-Castillejos, J. Alcocer-Varela, J. Granados, S. Bahena, P. Galanaud and D. Emilia. 1997. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. *Arthritis Rheum.* 38: 1429.
37. Westendorp, R.G.J., J.A.M. Langermans, T.W.G. Huizinga, A.H. Elouali, C.L. Verweij and J.P. Vandenbroucke. 1997. Genetic influence on cytokine production and fatal meningococcus disease. *Lancet.* 349:170.
38. Eskdale, J., G. gallagher, C.L. Vermeij, V. Keijsers, R.G.J. Westendorp and T.W.J. Huizinga. 1998. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. *Proc. Natl. Acad. Sci. USA.* 95: 9465-9470.
39. Derkx, B., A. marchant, M. Goldman, R. Biilmer and S. Van de Venter. 1995. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. *J. Infect. Dis.* 171: 229.
40. Llorente, L., Y. Richaud-Patin, R. Fior, J. Alcocer-Varela, J. Wijdnes, B. Morel-Fourrier, P. Galanaud and P. Emilie. 1994. In vivo production of interleukin-10 by non -T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocytes hyperactivity and autoimmunity. *Arthritis Rheum.* 37: 1647.

41. Cash, J.J., J.B. Splawski, R. Thomas, J.F. McFarlin, H. Schulze-Koops, L.S. Davis, K. Fujita and P.E. Lipsky. 1995. Elevated interleukin-10 levels in patients with rheumatoid arthritis. *Arthritis Rheum.* 38: 96.
42. Eskdale, J. P. Wordsworth, S. Bowman, M. Field and G. Gallagher. 1997. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. *Tissue Antigens.* 49: 635.
43. Zheng, C., D. Huang, L. Liu, R. Wu, S. Bergenbrant Glas, A. Osteborg, M. Bjorkholm, G. Holm, Q. Yi, A. Sundblad. 2001. Interleukin-10 gene promoter polymorphisms in multiple myeloma. *Int. J. Cancer.* 95: 184.
44. Via, C.S., G.C.Tsokos, N.I. Stocks, M. Clerici and G.M. Shearer. 1990. Human in vitro allogeneic responses: demonstration of three pathways of T helper cell activation. *J. Immunol.* 144:2524.
45. Hahn, A.B., J.C. kasten-Jolly, D. M. Costantino, E. Graffunder, T.P. Singh, G.K. Shen and D.J. Conti. 2001. Tnf-a, Il-6, IFN-g, and IL-10 gene expression polymorphisms and the IL-4 receptor a-chain variant Q576R: effects on renal allograft outcome. *Transplantation.* 72: 660.
46. Lio, D., G. Candore, A. Colombo, G. Colonna Romano, F. Gervasi, V. Marino, L. Scola and C. Caruso. 2001. A genetically determined high setting of TNF-alpha influences immunologic parameters of HLA-B8, DR3 positive subjects: implications for autoimmunity. *Hum Immunol.* 62: 705.
47. Akdis, C.A., and K. Blaser K. 2001. Mechanisms of interleukin-10-mediated immune suppression. *Immunol.* 103:131.

48. Segal, B.M., B.K. Dwyer and E.M. Shevach. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease *J Exp Med* 187: 537.
49. Bagli M, Papassotiropoulos A, Knapp M, Jessen F, Rao ML, Maier W, Heun R. association between an interleukin-6 and 3' flanking region haplotype and reduced Alzheimer's risk in German population. *Neurosci Lett* 2000; 283: 109-112.
50. Bowcock AM, Kidd JR, Lathrop GM, Daneshvar L, May LT, ray A, Sehgal PB, Kidd KK, Cvall-Sforza LL. The human "interferon-beta 2/hepatocyte stimulating factor/IL-6" gene: DNA polymorphism studies and localization to chromosome 7p21. *Genomics* 1988; 3(1): 8-16.
51. Campbell IL, Stalder AK, Chiang CS, Bellinger R, Heyser CJ, Steffensen S, Masliah E, Powell HC, Gold LH, henriksen SJ, Siggins GR. Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. *Mol Psychiatry* 1997; 2: 125-129.
52. Chao CC, Molitor TW, Hu S. Neuroprotective role of IL-4 against activated microglia. *J Immunol* 1993; 151: 1473-1481.
53. Falcone E, Spadafora P, De Luca M, Ruffolo R, Brancati C, De Benedictis G. DYS19, D12S67, and D1S80 polymorphisms in population sample from southern Italy and Greece. *Hum Biol* 1995; 67(5): 689-701

54. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *J Clin Invest* 1998; 102 (7): 1369-76.
55. Goris A, Epplen C, Fiten P, Andersson M, Murru R, sciacca FL, Ronsse I; jackel S, Epplen JT, Marrosu MG, Olsson T, Grimaldi LM, Opdenakker G, Billiau A, Vandenbroeck K. Analysis of IFN-gamma gene (IFNG) polymorphism in multiple sclerosis in Europe: effect of population structure on association with disease. *J Interferon Cytokine Res* 1999; 19(9): 1037- 1046.
56. Kilpinen S, Hulkkonen J, Wang XY, Hurme M. The promoter polymorphism of the IL-6 gene regulates IL-6 production in neonates but not in adults. *Eur Cytokine Netw* 2001; 12 (1): 62-8.
57. Kim JM, Brannan CI, Copeland NG, Jenkins NA, Khan TA, Moore KW. Structure of the mouse IL-10 gene and chromosomal localisation of the mouse and human genes. *Journal of Immunology* 1992; 148: 3618.
58. Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafè M, Cavallone L, Franceschi C, Caruso C. Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. *Genes and Immunity* 2002; 3: 30-33.
59. Llorente L, Richaud-Patin Y, Couderc J, Alarcon-Segovia D, Ruiz-Soto R, Alcocer-Castillejos N, Alcocer-Varela J, Granados J, Bahena S, Galanaud P, Emilia D. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. *Arthritis Rheum* 1997;38(8): 1429-35.

60. Mateo I, Sanchez-Guerra M, Combarros O, Llorca J, Infante J, Gonzalez-Garcia J, del Molino JP, Berciano J. Lack of association between cathepsin D genetic polymorphism and Alzheimer disease in a Spanish sample. *Am J Med Genet* 2002; 114 (1): 31-3.
61. Murray RE, McGuigan F, Grant SF, Reid DM, Ralston SH. Polymorphisms of the interleukin-6 gene are associated with bone mineral density. *Bone* 1997; 21: 89-92.
62. Pallaud C, Stranieri C, Sass C, Siest G, Pignatti F, Visvikis S. Candidate gene polymorphisms in cardiovascular disease: a comparative study of frequencies between a French and an Italian population. *Clin Chem Lab Med* 2001; 39(2): 146-54.
63. Papassotiropoulos A, Hock C, Nitsch RM. Genetics of interleukin 6: implications for Alzheimer's disease. *Neurobiology of Aging* 1999;22: 863-871.
64. Pola R, Flex A, Gaetani E, Dal Lago A, Gerardini L, Pola P, Bernabei R. The -174 G/C polymorphism of the interleukin -6 gene promoter is associated with Alzheimer's disease in an Italian population. *Neuroreport* 2002; 13: 1645-1647.
65. Poli F, Nocco A, Berra S, Scalamogna M, Taioli E, Longhi , Sirchia G. Allele frequencies of polymorphisms of TNF- α , IL-6, IL-10 and IFNG in an Italian Caucasian population. *European journal of Immunogenetics* 2002; 29: 237-240.

66. Shibata N, Ohnuma T, Takahashi T, Baba H, Ishizuka T, Ohtsuka M, Ueki A, Nagao M, Arai H. Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. *American Journal of Medical Genetics* 2002; 114: 436-439.
67. Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B. detection of IL-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. *Lab Invest* 1992; 66: 223-30.
68. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. *J Biol Chem* 2000; 275 (24): 18138-44.
69. Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6 mediated "acute phase response" in the brain? *Immunol Today* 1991; 12: 217-19.
70. Vandenbroeck K, Hardt C, Louage j, Fiten P, Jackel S, Ronsse I, Epplen JT, Grimaldi LM, Olsson T, Marrosu MG, Billiau A, Opdenakker G. Lack of association between the interferon regulatory factor-1 (IRF1) locus at 5p31.1 and multiple sclerosis in Germany, northern Italy, Sardinia and Sweden. *Genes Immun* 2000; 1(4): 290-2.
71. Quintana FJ, Carmi P, Cohen IR. DNA vaccination with heat shock protein 60 inhibits cyclophosphamide-accelerated diabetes. *Journal of Immunology*. 169(10):6030-5, 2002 Nov 15.

72. Dalpke AH. Opper S. Zimmermann S. Heeg K. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. *Journal of Immunology*. 166(12):7082-9, 2001 Jun 15.
73. Yi AK. Yoon JG. Yeo SJ. Hong SC. English BK. Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. *Journal of Immunology*. 168(9):4711-20, 2002 May 1.
74. G. Hartmann et al., "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells," *Proceedings of the National Academy of Sciences*, 96:9305-10, 1999. Hollon T. Coley Toxin's Hidden message: from a 19th century mystery comes a potential new class of drugs: CpG oligonucleotides. *The Scientist* 15(5): 2001, March 5.
76. Hybridon's press release on May 07 2003 on data presented during the First Annual Meeting of the Federation of Clinical Immunology Societies held in Boston on May 4 to May 7, 2001, Posters#271"Modulation of immunostimulatory activity of CpG-oligonucleotides by incorporation of site-specific chemical modifications: Significance of internucleoside negative charge" Poster #229"Oligonucleotides containing YpG or CpR motifs as potent immunostimulatory agents", found on: <http://www.nrp-euro.com>.
77. Du Y. et al. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. *Neurology* 55(4): 464-5 2000, Aug 22

CLAIMS

1. A method of determining the existence of or a predisposition to Alzheimer's disease, autoimmune disease or other neurodegenerative diseases, the method comprising the steps of taking a DNA bearing sample from a subject animal and analysing the sample to determine the allelic variants present at one or more of the SNP loci at positions -1082, -819 and -592 of the gene encoding IL-10.
2. A method according to claim 1, in which the genotype at all three positions -1082, -819 and -592 is determined.
3. A method according to claim 1 or claim 2 which further comprises analysing the sample to determine the alleles present for the genes encoding IL-6 and Apo-E.
4. A method according to claim 3 which further comprises analysing the sample to determine the alleles present for the gene encoding IL-1.
5. A method of treating Alzheimer's disease, autoimmune disease or other neurodegenerative disorder which comprises augmenting the function of a gene having one of the allelic polymorphisms of IL-10 shown in Table I.
6. A method of treating Alzheimer's disease, autoimmune disease or other neurodegenerative disorder which comprises decreasing the function of a gene having one of the allelic polymorphisms of IL-10 shown in Table I.
7. A method according to claim 5 or claim 6 where the modulation of the function of the gene is by genetic therapy.

8. A method according to claim 5 or claim 6 where the modulation of the function of the gene is by pharmacological intervention.
9. A method according to claim 8 where the pharmacological intervention is using one or more compounds that enhance or inhibit antigen specific production of interleukin-10 and, optionally, one or more other cytokines.
10. A method according to any claim 9, characterised in that the other cytokine is selected from the group consisting of interleukin-1 (α or β), interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, interferon- α , interferon- β , interferon- γ , TNF- α , TNF- β , G-CSF, GM-CSF, M-CSF, and TGF- β .
11. DNA fragments and cDNA fragments comprising the allelic polymorphs of Table I for use in the method of claim 7.
12. Use of the DNA or cDNA fragments of claim 11 in a method of screening compounds for the ability to modulate the allelic polymorphisms of Table I.
13. Use of the DNA or cDNA fragments of claim 11 in a method of screening compounds for the ability to modulate or prevent Alzheimer's disease.
14. Use of cytokines in the preparation of a medicament for the treatment or prophylaxis of diseases which are not neoplastic.
15. Use according to claim 14, characterised in that the disease is a neurodegenerative disorder or an autoimmune disorder.


16. Use according to claim 14 or claim 15, characterised in that the use is for Alzheimer's disease.
17. Use according to any one of claims 14 to 16, characterised in that the cytokine is selected from interleukin-1 (α or β), interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, interferon- α , interferon- β , interferon- γ , TNF- α , TNF- β , G-CSF, GM-CSF, M-CSF, and TGF- β .

(USPTO)

Y

THIS PAGE BLANK (USPTO)

Figure 1




DT09 Rec'd PCT/PTO 29 NOV 2004

THIS PAGE BLANK (USPTO)

Y

D

Figure 2.







DT09 Rec'd PCT/PTO 29 NOV 2004

THIS PAGE BLANK (USPTO)

I

Y

Figure 3



B. Y.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 03/02369

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G01N33/68 G01N33/74

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, BIOSIS, EPO-Internal, MEDLINE, WPI Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	LIO D ET AL: "Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease." GENES AND IMMUNITY, vol. 4, no. 3, April 2003 (2003-04), pages 234-238, XP001155652 ISSN: 1466-4879 (ISSN print) page 236; tables 1,2	1-3, 11
Y	REMARQUE E J ET AL: "Patients with Alzheimer's disease display a pro-inflammatory phenotype" EXPERIMENTAL GERONTOLOGY, vol. 36, no. 1, January 2001 (2001-01), pages 171-176, XP002257920 ISSN: 0531-5565 page 173 -page 175; table 1 --- -/--	1-17



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

15 October 2003

Date of mailing of the international search report

10/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Trommsdorff, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/02369

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TURNER D M ET AL: "AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN-10 GENE PROMOTER" EUROPEAN JOURNAL OF IMMUNOGENETICS, OXFORD, GB, vol. 24, no. 1, 1997, pages 1-8, XP000865679 ISSN: 0960-7420 page 6; figure 1 ---	1-17
Y	PAPASSOTIROPOULOS ANDREAS ET AL: "Genetics of interleukin 6: Implications for Alzheimer's disease" NEUROBIOLOGY OF AGING, vol. 22, no. 6, November 2001 (2001-11), pages 863-871, XP002257921 ISSN: 0197-4580 page 867, left-hand column -page 868, left-hand column ---	3,10
Y	WO 95 33992 A (MOR RESEARCH APPLIC LTD ;UNIV BAR ILAN (IL); SHALIT FRANCES (IL)) 14 December 1995 (1995-12-14) figures 1-6 ---	3,10
Y	MARTIN E R ET AL: "SNPING AWAY AT COMPLEX DISEASES: ANALYSIS OF SINGLE-NUCLEOTIDE POLYMORPHISMS AROUND APOE IN ALZHEIMER DISEASE" AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 67, August 2000 (2000-08), pages 383-394, XP000995224 ISSN: 0002-9297 page 384 -page 385 ---	3,10
T	DEPBOYLU CANDAN ET AL: "Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease." NEUROSCIENCE LETTERS, vol. 342, no. 1-2, 15 May 2003 (2003-05-15), pages 132-134, XP001155649 ISSN: 0304-3940 (ISSN print) the whole document --- -/--	

INTERNATIONAL SEARCH REPORT

International Publication No.

PCT/GB 03/02369

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SZCZEPANIK A M ET AL: "IL-4, IL-10 and IL-13 modulate ab(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line" JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 113, no. 1, 2001, pages 49-62, XP002955731 ISSN: 0165-5728 the whole document</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 03/02369

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 11
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-4 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 5-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

With regard to claims 12 and 13 only in vitro methods have been considered.

Continuation of Box I.2

Claims Nos.: 11

Present claim 11 relates to a compound defined by reference to a desirable characteristic or property, namely its ability to modulate IL-10 expression.

The claim covers all compounds having this characteristic or property, whereas the application does not provide support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any compound with said property. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search has been carried out for claim 11.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/02369

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9533992	A	14-12-1995	AU 2823895 A	04-01-1996
			EP 0760098 A1	05-03-1997
			WO 9533992 A1	14-12-1995
			US 5874312 A	23-02-1999
<hr/>				